A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 binding. The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs). We also observe that pre-existing CTLs within the tumor are sufficient and essential for sumIL-2 therapy. This next-generation IL-2 can also overcome targeted therapy-associated resistance. In addition, preoperative sumIL-2 treatment extends survival much longer than standard adjuvant therapy. Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade through concurrent immunotherapies. Therefore, this next-generation IL-2 reduces toxicity while increasing TILs that potentiate combined cancer therapies.

Original languageEnglish (US)
Article number3874
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

T-cells
Interleukin-2
Tumors
therapy
tumors
T-Lymphocytes
antibodies
lymphocytes
Neoplasms
toxicity
cancer
Cytotoxic T-Lymphocytes
Toxicity
Antibodies
Therapeutics
half life
Neoplasm Antibodies
Regulatory T-Lymphocytes
Natural Killer Cells
Immunotherapy

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. / Sun, Zhichen; Ren, Zhenhua; Yang, Kaiting; Liu, Zhida; Cao, Shuaishuai; Deng, Sisi; Xu, Lily; Liang, Yong; Guo, Jingya; Bian, Yingjie; Xu, Hairong; Shi, Jiyun; Wang, Fan; Fu, Yang-Xin; Peng, Hua.

In: Nature communications, Vol. 10, No. 1, 3874, 01.12.2019.

Research output: Contribution to journalArticle

Sun, Z, Ren, Z, Yang, K, Liu, Z, Cao, S, Deng, S, Xu, L, Liang, Y, Guo, J, Bian, Y, Xu, H, Shi, J, Wang, F, Fu, Y-X & Peng, H 2019, 'A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control', Nature communications, vol. 10, no. 1, 3874. https://doi.org/10.1038/s41467-019-11782-w
Sun, Zhichen ; Ren, Zhenhua ; Yang, Kaiting ; Liu, Zhida ; Cao, Shuaishuai ; Deng, Sisi ; Xu, Lily ; Liang, Yong ; Guo, Jingya ; Bian, Yingjie ; Xu, Hairong ; Shi, Jiyun ; Wang, Fan ; Fu, Yang-Xin ; Peng, Hua. / A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{51131417615d4527a17ea7afca64086a,
title = "A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control",
abstract = "While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 binding. The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs). We also observe that pre-existing CTLs within the tumor are sufficient and essential for sumIL-2 therapy. This next-generation IL-2 can also overcome targeted therapy-associated resistance. In addition, preoperative sumIL-2 treatment extends survival much longer than standard adjuvant therapy. Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade through concurrent immunotherapies. Therefore, this next-generation IL-2 reduces toxicity while increasing TILs that potentiate combined cancer therapies.",
author = "Zhichen Sun and Zhenhua Ren and Kaiting Yang and Zhida Liu and Shuaishuai Cao and Sisi Deng and Lily Xu and Yong Liang and Jingya Guo and Yingjie Bian and Hairong Xu and Jiyun Shi and Fan Wang and Yang-Xin Fu and Hua Peng",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-11782-w",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

AU - Sun, Zhichen

AU - Ren, Zhenhua

AU - Yang, Kaiting

AU - Liu, Zhida

AU - Cao, Shuaishuai

AU - Deng, Sisi

AU - Xu, Lily

AU - Liang, Yong

AU - Guo, Jingya

AU - Bian, Yingjie

AU - Xu, Hairong

AU - Shi, Jiyun

AU - Wang, Fan

AU - Fu, Yang-Xin

AU - Peng, Hua

PY - 2019/12/1

Y1 - 2019/12/1

N2 - While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 binding. The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs). We also observe that pre-existing CTLs within the tumor are sufficient and essential for sumIL-2 therapy. This next-generation IL-2 can also overcome targeted therapy-associated resistance. In addition, preoperative sumIL-2 treatment extends survival much longer than standard adjuvant therapy. Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade through concurrent immunotherapies. Therefore, this next-generation IL-2 reduces toxicity while increasing TILs that potentiate combined cancer therapies.

AB - While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 binding. The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs). We also observe that pre-existing CTLs within the tumor are sufficient and essential for sumIL-2 therapy. This next-generation IL-2 can also overcome targeted therapy-associated resistance. In addition, preoperative sumIL-2 treatment extends survival much longer than standard adjuvant therapy. Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade through concurrent immunotherapies. Therefore, this next-generation IL-2 reduces toxicity while increasing TILs that potentiate combined cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=85071378954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071378954&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-11782-w

DO - 10.1038/s41467-019-11782-w

M3 - Article

C2 - 31462678

AN - SCOPUS:85071378954

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 3874

ER -